UPDATE 2-US FDA turns down full approval of Amgen lung cancer drug Lumakras
“Dec 26 (Reuters) – The U.S. health regulator on Tuesday declined to grant traditional approval to Amgen’s Lumakras for treating lung cancer patients with a specific gene mutation, although it kept the drug’s existing accelerated approval status.”
Tarlatamab Demonstrates Activity in Relapsed/Refractory SCLC
“Tarlatamab can produce durable responses in patients with relapsed or refractory small cell lung cancer (SCLC), according to research published in The New England Journal of Medicine. These results, from the phase 2 DeLLphi-301 trial, are being used to support the biologics license application for tarlatamab to treat adults with advanced SCLC who have disease progression on or after platinum-based chemotherapy.”
Listening to Her Angel Helps Slatington Woman Beat Lung Cancer
“One day, Joyce Flack got a letter in the mail about a lung cancer screening and made a decision that may have saved her life”
Bristol Myers to buy cancer therapy company in $4.1 billion deal
“Bristol Myers Squibb on Tuesday announced a deal to acquire RayzeBio in an effort to expand the drugmaker’s cancer treatment offerings. RayzeBio, a clinical-stage radiopharmaceutical therapeutics (RPT) company, has several cancer treatments under development, specifically ones targeting the treatment of solid tumors, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs), small cell lung cancer, hepatocellular carcinoma and other cancers, according to a press release.”
Protein-Based Risk Model Versus Existing Lung Cancer Prediction Tools
“A protein-based risk model is superior in predicting lung cancer compared with two existing prediction tools, according to Xiaoshuang Feng, PhD, and colleagues.”
A Year of Triumphs in Oncology: 2023 FDA Approvals
“LUNG CANCER
JANUARY 26: The FDA approves adjuvant pembrolizumab (Keytruda) following resection and platinum-based chemotherapy for stage IB (T2a ≥ 4 cm), II, or IIIA non–small cell lung cancer (NSCLC).
AUGUST 9: The FDA approves the RET tyrosine kinase inhibitor pralsetinib (Gavreto) for the treatment of adult patients with metastatic RET fusion–positive NSCLC as detected by an FDA-approved test.
OCTOBER 11: The FDA approves the combination of encorafenib (Braftovi) and binimetinib (Mektovi) for patients with metastatic NSCLC harboring a BRAF V600E mutation, as detected by an FDA-approved test.
OCTOBER 16: The FDA approves perioperative pembrolizumab (Keytruda) in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as a single agent in the adjuvant setting for the treatment of patients with resectable stage II, IIIA, or IIIB (T3-4N2) NSCLC.
NOVEMBER 15: The FDA has granted approval to repotrectinib (Augtyro), a tyrosine kinase inhibitor, for the treatment of patients with ROS1-positive locally advanced or metastatic non–small cell lung cancer.”
22 Cancer Groups Urge Biden to Support Ending Sale of Menthol, Flavored Smokes
“Ending the sale of menthol in cigarettes and flavors in cigars is key to achieving Cancer Moonshot goals, notably among Black Americans.”
SENATE PASSES RUBIO, SMITH RESOLUTION TO RECOGNIZE NOVEMBER AS NATIONAL LUNG CANCER AWARENESS MONTH
“U.S. Senators Marco Rubio (R-FL) and Tina Smith (D-MN) applauded the Senate passage of their resolution to designate November 2023 as National Lung Cancer Awareness Month. The resolution recognizes the need for more research to improve early diagnosis, screening, and treatment.”
A known carcinogen is showing up in wildfire ash, and researchers are worried
“It’s widely known that wildfire smoke is bad for your health, but a group of researchers recently found a known carcinogen in California wildfire ash, raising concerns about just how harmful it could be to breathe the air near a blaze. According to a study released in Nature Communications last week, researchers discovered dangerous levels of hexavalent chromium in samples of ash left behind by the Kincade and Hennessey fires in 2019 and 2020.”
